Keynote Trials for Pediatric Cancers

As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.

Below are trials currently being conducted in pediatric cancers, evaluating the investigational study drug, pembrolizumab (MK-3475).

Active Clinical Trials

The cancer types listed below currently have active trial listings on clinicaltrials.gov. Click on a study name to be directed to that trial's information, or call 1-888-577-8839 to find a study site near you for the trial you are interested in.

Keynote Study for Pediatric Lymphoma

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

This is a 2-part study of pembrolizumab in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or lymphoma. Part 1 will find the maximum tolerated dose (MTD)/maximum administered dose (MAD), confirm the dose, and find the recommended Phase 2 dose (RP2D) for pembrolizumab therapy. Part 2 will further evaluate the safety and efficacy at the pediatric RP2D.

more about the study

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.